{
    "nct_id": "NCT04696731",
    "official_title": "A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
    "inclusion_criteria": "* Histologically confirmed renal cell carcinoma with a predominant clear cell component.\n* Must have received a checkpoint inhibitor and a VEGF inhibitor in the advanced and/or metastatic setting.\n* At least one measurable lesion as defined by RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.\n* Absence of donor (product)-specific anti-HLA antibodies (DSA).\n* Adequate hematological, renal, liver, pulmonary, and cardiac functions.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Central nervous system (CNS) metastatic disease (unless controlled and stable for at least 4 weeks), leptomeningeal disease, or cord compression.\n* Clinically significant CNS dysfunction.\n* Any other active malignancy within 3 years prior to enrollment.\n* Prior treatment with anti-CD70 therapies.\n* Current thyroid disorder (including hyperthyroidism) with the exception of hypothyroidism controlled on stable dose of hormone replacement therapy.\n* Prior treatment with anti-CD52 monoclonal antibody in the past 12 months.\n* Patients unwilling to participate in the extended safety monitoring period.",
    "miscellaneous_criteria": ""
}